Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

As always, I am looking to improve the overall quality of my portfolio in 2024. Humana's total revenue and adjusted EPS grew at healthy clips in the third quarter. The company's interest coverage ratio was above 12 through the first three quarters of 2023.

Humana: Buy This Powerful Dividend Growth Stock In The New Year

Abbott Labs

McKesson

Finding investment opportunities in tune with today's demographic trends can be challenging, but aging population stocks may be the solution. This market is booming in a world with an aging population, creating a special opportunity for investors to profit.

Silver Economy Successes: 3 Stocks Benefitting From an Aging Population

The latest trading day saw Humana (HUM) settling at $453.94, representing a +0.45% change from its previous close.

Humana (HUM) Advances But Underperforms Market: Key Facts

Bio-Rad Laboratories

Bristol-Myers

Cigna

Incyte

Moderna

After an abysmal year for healthcare stocks, Wall Street is upbeat on Cigna, Humana, Bristol Myers, and three others.

6 Stock Picks in Healthcare for 2024

Centene

Molina Healthcare

UnitedHealth Group

Medical-HMO stocks like UNH, HUM, CNC and MOH are expected to reap the benefits of an aging U.S. population and growing premiums in 2024. However, challenges related to the resumption of elective procedures might play spoilsport.

4 Health Insurers Likely to Maintain Winning Streak in 2024

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Humana (HUM) is a Strong Value Stock

Humana (HUM) concluded the recent trading session at $461.46, signifying a -1.62% move from its prior day's close.

Humana (HUM) Falls More Steeply Than Broader Market: What Investors Need to Know

LOUISVILLE, Ky.--(BUSINESS WIRE)--Leading US health insurer and health care services company Humana Inc. (NYSE: HUM) has earned a score of 100 percent on the Human Rights Campaign Foundation Corporate Equality Index and the designation as one of the Best Places to Work for LGBTQ+ Equality for the tenth year in a row. The recognition reflects Humana's deep commitment to creating a culture of belonging where each employee feels valued and has both opportunity and support to reach their full poten.

Humana Earns Top Score in Human Rights Campaign Foundation's 2023 Corporate Equality Index

Eli Lilly

U.S. equities were little changed at midday ahead of key inflation data due later in the week and the final Federal Reserve policy meeting of 2023. The Dow and S&P 500 were up slightly, while the Nasdaq was in the red.

Midday Movers: Cigna Soars After Calling Off Humana Deal, Eli Lilly Falls Following Study

US health insurer Cigna (NYSE:CI) has abandoned plans to merge with Humana (NYSE:HUM), a transaction that would have created a $140 billion insurance giant, according to reports. The Financial Times said disagreement over financial arrangements, regulatory fears and falling share prices following reports of the potential tie-up drove Cigna's decision to halt plans, citing people with knowledge of the deal.

Cigna plans bumper buyback amid reports Humana merger talks end

Cigna (NYSE: CI ) has ditched its plans to acquire Humana (NYSE: HUM ), another huge health insurer. Instead, Cigna will buy back $10 billion of its own shares and carry out smaller M&A deals.

CI Stock Alert: Cigna Ditches Humana Acquisition for $10 Billion Stock Buyback

Cigna said it will consider smaller, "bolt-on" acquisitions in the near term, but did not confirm the reports about its abandoned pursuit of Humana.

Cigna shares jump on reports of abandoned Humana buyout, plans for $10 billion stock buyback

The proposed merger between Cigna and Humana being called off is expected to result in a relief rally for both stocks. Walmart is speculated to be interested in acquiring Humana, which could lead to a higher offer and less regulatory scrutiny than the previous merger proposal. Humana is a fundamentally strong business with consistent revenue growth, investor-friendly practices, and a reasonably priced stock.

Humana: Failed Merger And Other Reasons To Buy

Cigna and Humana called off a potentially massive merger. The deal between the two companies would have created a $140 billion conglomerate.

A merger between Cigna and Humana that would have created a gigantic $140 billion healthcare conglomerate has been called off

Managed-care provider Cigna Group on Sunday announced a massive stock buyback, amid a report that it has abandoned its bid to buy rival Humana Inc.

Cigna raises stock buyback by $10 billion, will reportedly drop bid to buy Humana

Cigna hiked its stock buyback by $10 billion on Sunday. The health insurer has ended talks to buy Humana, The Wall Street Journal reported.

Cigna Reportedly Ends Humana Takeover Push, Hikes Buyback By $10 Billion

U.S. health insurer Cigna has ended its attempt to negotiate an acquisition of peer Humana, two sources familiar with the situation said on Sunday, plans to buy back $10 billion worth of shares. The deal could have exceeded $60 billion in value but was certain to attract fierce antitrust scrutiny.

US health insurer Cigna scraps $10B deal to buy Humana: report

U.S. health insurer Cigna has called off its deal to buy Humana , scrapping a deal that could have created a roughly $140 billion giant in the health-insurance industry, the Wall Street Journal reported on Sunday

US health insurer Cigna scraps deal to buy Humana -WSJ

The health-insurance providers couldn't agree on financial terms for a deal that would have created a $140 billion giant.

Cigna Calls Off Humana Pursuit, Plans Big Stock Buyback

LOUISVILLE, Ky.--(BUSINESS WIRE)--HUMANA SETS AMBITIOUS SCIENCE-BASED ENVIRONMENTAL TARGETS TO REDUCE EMISSIONS BY 54.6 PERCENT.

Humana Sets Ambitious Science-Based Environmental Targets to Reduce Emissions by 54.6 Percent

RICHMOND, Va.--(BUSINESS WIRE)--Humana announces $500K investment in the Virginia Health Care Foundation to boost behavioral health workforce development and support.

Humana Announces $500K Investment in the Virginia Health Care Foundation to Boost Behavioral Health Workforce Development and Support

COLLEGE STATION, Texas--(BUSINESS WIRE)--Texas A&M University-Mays Business School and Humana announce 7th annual Healthcare Analytics Case Competition winners.

Texas A&M University-Mays Business School and Humana Announce Seventh Annual Healthcare Analytics Case Competition Winners

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Foundation Awards Health Equity Research Grants Equal to $1 Million to Three University Partners.

Humana Foundation Awards Health Equity Research Grants Equal to $1 Million to Three University Partners

Consolidation in the health insurance industry has become a theme of 2023. Humana Inc. NYSE: HUM is reportedly in talks to merge with The Cigna Group NYSE: CI in a stock-and-cash deal.

Mega merger in the works? Humana, Cigna explore big deal

Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.

News for Humana Stock (HUM)